Effects of tyrosine kinase inhibitor-masitinib mesylate on canine mammary tumour cell lines

Abstract

Masitinib mesylate, a selective tyrosine kinase inhibitor of the c-KIT receptor, is used for the treatment of mast cell tumours in dogs. Masitinib has previously been investigated in various cancers; however, its potential anticancer effect in canine mammary tumours (CMTs) is unknown. In the present paper, we investigated the antiproliferative effect of masitinib in CMT cells and its possible mechanisms of action.

Keywords

• tyrosine kinase inhibitor
• masitinib
• canine mammary cancer
• apoptosis
• vegf